-

Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.

Conference Call Details

Date:

Wednesday, May 3, 2023

Time:

8:00 a.m. ET

Webcast:

https://www.webcaster4.com/Webcast/Page/2883/47444

Participant Event Dial-in:

+1 (888) 506-0062 (North America)

+1 (973) 528-0011 (International)

Participant Access Code:

937525

Replay Dial-in:

+1 (877) 481-4010 (North America)

+1 (919) 882-2331 (International)

Replay Passcode:

47444 (replay available until May 17, 2023)

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

© 2023 Bausch & Lomb Incorporated or its affiliates.

Contacts

Investor Contacts:
Arthur Shannon
Arthur.shannon@bausch.com

Allison Ryan
allison.ryan@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Media Contacts:
Lainie Keller
lainie.keller@bausch.com
(908) 927-1198

Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Investor Contacts:
Arthur Shannon
Arthur.shannon@bausch.com

Allison Ryan
allison.ryan@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Media Contacts:
Lainie Keller
lainie.keller@bausch.com
(908) 927-1198

Kristy Marks
kristy.marks@bausch.com
(908) 927-0683

More News From Bausch + Lomb Corporation

Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in January. Bausch + Lomb will also sponsor The Glaucoma Foundation’s (TGF) social media campaign to raise awareness of the disease and its impact by highlighting a glaucoma patient or advocate every day i...

Bausch + Lomb Completes Refinancing of Outstanding Term B Loans

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connection with the closing, Bausch + Lomb has entered into a fourth amendment (the “Fourth Amendment”) to its existing credit agreement providing for a $2,802,125,000 tranche (the “Replacement Term Loans”...

Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, MD, will participate in a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026, at...
Back to Newsroom